Acrux Limited · ASX:ACR
Acrux — Investor Presentation (March 2007)
24 slides from Acrux's investor presentation, Mar 21, 2007
Slide 1: ly om
ly om eon , L Yee y ye i i TO oe Lo TT bg \ iN) : 7 Sl c es y y Bae U1] iit itn nt ihinnttTtt a . ww Lo = Lo DEVELOPIN RANGE OF PATIEN _. i PHARMACE! P| : LM _ — oo ee Se — CC a Se TTT at
Slide 2: Forward-looking statements
This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Acrux to be materially different from the statements in this pres
Slide 3: Proven technology
oN Proven technology — First product successfully through Phase 3 in USA and in registration — Other products use same delivery technology Access to major markets — Broad core patents to 2017 granted in USA and Europe, pending elsewhere -» New patents pending out to 2026 Expert management -—» New le
Slide 4: Safety and patient utility
e i: li hhh ie Ta : _ a ee a iG — SAFETY 7 Ly ie ~~ PATIENT UTILITY
Slide 5: Acrux Patchless Patch Reservoir
AcRUX Patchless Patch® Reservoir TECHNOLOGY PLATEORS ent. achoss enlaces Forms an invisible reservoir within the skin US Pat. no. 6,818,226 (expires 2017) ACROSS® Enhancers « Allow drugs to pass through skin more rapidly ® : ves Applicator ee | GRAS status Used for simple, accurate & i ie US Pat. no
Slide 6: Apply delivery technology to proven drugs
Lo « Apply delivery technology to proven drugs — abbreviated development with lower cost and less risk « Progress products through clinical and regulatory milestones sufficient to prove commercial value « Commercialise in major pharmaceutical markets through licensing intellectual property — licence
Slide 7: Management team
a) Richard Treagus, CEO Jon Pilcher, CFO Nina Wilkins, Director, BD Hugh Alsop, Director, BD Former Sigma, Aspen, Roche | Former ANZ, Celltech (US, Japan, ANZ) (EU, Asia, Middle East) Former Wyeth Former Sigma, Mayne Adam Watkinson, CSO Tim Saunders, Director, ; Former ProStrakan Project Management
Slide 8: Research and business development leaders
yy es et, Lo CUES SU Dr Adam Watkinson Tim Saunders Dr Richard T reagus TT ain 7 oo - 7 : Vee a —New compounds Testosterone MD-Lotion® —Partner Performance —Technology improvements —Fentanyl UDTS™ —New Licence Agreements — Synergistic technologies —Contraceptive sprays — Collaborative Agreements 2 o
Slide 9: Organon licensing deals
¢ Healthcare business of Akzo Nobel; a leader in women’s health - number 3 in US$6.7 billion global contraception market * Two separate worldwide licence deals - Organon funds all clinical, regulatory and commercialisation Organon selects contraceptive compounds for development as spray Acrux earns
Slide 10: Target market and pipeline
Target market ‘ $n) Formulation Phase1PK Phase 2PK Phase 3 Registration Current Partner Therapeutic Area efficacy Menopausal symptom: : FvaMist!™ (Est Decreased libide in women Contraception Chronic pain entanyl UDTS™ Male testosterone deficiency ‘Testosterone MD-Lotion| g Yj Companion animal health
Slide 11: Product pipeline by therapeutic area
ene Therapeutic Area {US$bn) Menopausal symptoms Decreased libide in women Contraception Chronic pain Male testosterone deficiency Formutation PhaseiPK Phase 2PK Testosterone MD-Lotion” ORT Phase 2 efficacy OLLIE. CLL Phase 3 Registration Partners UMMA Potential
Slide 12: EvaMist US marketing application
* US marketing application submitted by VIVUS and accepted by FDA * US$3m due from VIVUS on approval of application, then royalties * US estrogen-alone therapy market US$1.3 billion — Estrogen is most effective treatment for menopause symptoms — Transdermal estradiol has safety advantages over estro
Slide 13: Testosterone MD-Lotion
Global market US$0.6 billion, dominated by Androgel® US market research confirms strong patient preference for Acrux’s convenient and discreet lotion over current therapies Patent pending protects unique application to the armpit until 2026 Phase 2 trial in progress in USA under IND; results due mid
Slide 14: Cash reserves and revenue sources
One * Cash reserves $18m - cash outflow FY 2005/06 $8.3m « Priority to grow revenue from new & existing licences * Research and commercialisation are scalable at fixed cost — development costs are variable and controllable « Target is revenue growth to drive profitability in 2008 « Existing licensin
Slide 15: Share ownership
0 SHARE OWNERSHIP (TOTAL 142.6m) institutions 40% other / retail 48% directors & | 6.4m (4.5%) employee options outstanding managers at prices 69¢ to $1.20 12% Controlled improvement in register quality: — Nov 2006 to Feb 2007; former CEO options expiry — 8m shares placed/sold —Oct 2006; 2 year escr
Slide 16: Acrux share price and market cap comparison
Cents per Share a0 400 40 Acrux (ACR) share price July 2005 - Feb 2007 Market cap 6 Feb 2007! $m Novogen 310 Progen 308 Biota 291 Ventracor 238 Clinuvel 230 Phosphagenics 187 Alchemia 150 Juk05 = SepO0S = NowOS = dan08 ss Apr-06 lun. O6 = ALO Now Jan.07 : Heartware 145 —» Focus on a single technolog
Slide 17: Achievements in the past year
Organon — 2 licensing deals signed with one of the global leaders in contraception and women’s health; Evamist™ - VIVUS filed Evamist marketing application with FDA; US$1m received Testosterone MD-Lotion® - started final Phase 2 trial Animal Health — Elanco licence expanded to add additional therape
Slide 18: Milestones for 2007
HS Licensing - secure significant new deal (2 deals achieved) EvaMist™ - VIVUS files marketing application with FDA (achieved) Testosterone MDTS® - VIVUS starts Phase 3 trials Contraceptive sprays - start proof of concept trials of combinations Testosterone MD-Lotion® - complete Phase 2 trials New p
Slide 19: cs y oy
cs y oy cc
Slide 20: Key advantages
I * Key advantages — Steady, continuous delivery — BLOOD — Sustained efficacy, reduced toxicity LeveL oF DRUG — Lower dose frequency leads to increased patient compliance —*, — Works for many injectable drugs 6 a 8 24 TIME (HOURS) « Acrux overcomes traditional patch disadvantages —Dosage limitations
Slide 21: Comparison with patches
: ie 1970 1990 No or low risk of skin irritation v x v Cosmetic acceptability x x v Dosage flexibility x x v Ease of manufacture x x v Cost effective v x v Range of applications x v v x x v Preference by patients
Slide 22: Market research with post-menopausal women
¢ Market research with 200 women of post-menopause age — Patch or implant hormone therapy users — 100% would switch to MDTS® — Tablet hormone therapy users — 88% would switch to MDTS® ¢ Backed up in studies conducted by others ¢ Current annual US market for estrogen therapy — Patches/gels: US$0.3 bi
Slide 23: EvaMist Phase 3 hot flush results
457 postmenopausal women — changes in frequency and severity of moderate to severe hot flushes after 4 and 12 weeks with EvaMist™ or placebo spray All FDA efficacy and safety endpoints met Frequency of Moderate to Severe Hot Flashes 15 3 a Moderate to Severe Hot Flashes per Day Baseline 4 week B wee
Slide 24: EvaMist to launch in 2007
First product EvaMist™ to launch in 2007 after 7 years development Nestorone & Testosterone for women are exceptions — require Phase 2 efficacy and longer Phase 3